vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and MID PENN BANCORP INC (MPB). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $62.0M, roughly 1.4× MID PENN BANCORP INC). MID PENN BANCORP INC runs the higher net margin — 31.4% vs 22.8%, a 8.6% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 30.8%). MID PENN BANCORP INC produced more free cash flow last quarter ($71.8M vs $28.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 21.1%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
FDMT vs MPB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $62.0M |
| Net Profit | $19.4M | $19.4M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 43.6% |
| Net Margin | 22.8% | 31.4% |
| Revenue YoY | 8508900.0% | 30.8% |
| Net Profit YoY | 139.1% | 47.0% |
| EPS (diluted) | $0.43 | $0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $62.0M | ||
| Q3 25 | $90.0K | $61.8M | ||
| Q2 25 | $15.0K | $54.3M | ||
| Q1 25 | $14.0K | $47.7M | ||
| Q4 24 | $1.0K | $47.4M | ||
| Q3 24 | $3.0K | $45.3M | ||
| Q2 24 | $5.0K | $44.1M | ||
| Q1 24 | $28.0K | $42.3M |
| Q4 25 | $19.4M | $19.4M | ||
| Q3 25 | $-56.9M | $18.3M | ||
| Q2 25 | $-54.7M | $4.8M | ||
| Q1 25 | $-48.0M | $13.7M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $-43.8M | $12.3M | ||
| Q2 24 | $-35.0M | $11.8M | ||
| Q1 24 | $-32.4M | $12.1M |
| Q4 25 | 17.3% | 43.6% | ||
| Q3 25 | -67983.3% | 39.3% | ||
| Q2 25 | -396373.3% | 7.9% | ||
| Q1 25 | -383007.1% | 35.2% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | -1704400.0% | 32.8% | ||
| Q2 24 | -849120.0% | 32.4% | ||
| Q1 24 | -136200.0% | 34.8% |
| Q4 25 | 22.8% | 31.4% | ||
| Q3 25 | -63195.6% | 29.6% | ||
| Q2 25 | -364386.7% | 8.8% | ||
| Q1 25 | -342657.1% | 28.8% | ||
| Q4 24 | — | 27.9% | ||
| Q3 24 | -1461433.3% | 27.1% | ||
| Q2 24 | -699060.0% | 26.7% | ||
| Q1 24 | -115717.9% | 28.7% |
| Q4 25 | $0.43 | $0.83 | ||
| Q3 25 | $-1.01 | $0.79 | ||
| Q2 25 | $-0.98 | $0.22 | ||
| Q1 25 | $-0.86 | $0.71 | ||
| Q4 24 | — | $0.72 | ||
| Q3 24 | $-0.79 | $0.74 | ||
| Q2 24 | $-0.63 | $0.71 | ||
| Q1 24 | $-0.66 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $814.1M |
| Total Assets | $566.7M | $6.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | — | ||
| Q3 25 | $305.1M | — | ||
| Q2 25 | $293.2M | — | ||
| Q1 25 | $321.4M | — | ||
| Q4 24 | $424.9M | — | ||
| Q3 24 | $501.9M | — | ||
| Q2 24 | $541.9M | — | ||
| Q1 24 | $525.9M | — |
| Q4 25 | $505.7M | $814.1M | ||
| Q3 25 | $369.0M | $796.3M | ||
| Q2 25 | $420.9M | $775.7M | ||
| Q1 25 | $469.7M | $667.9M | ||
| Q4 24 | $510.6M | $655.0M | ||
| Q3 24 | $552.9M | $573.1M | ||
| Q2 24 | $588.3M | $559.7M | ||
| Q1 24 | $600.6M | $551.0M |
| Q4 25 | $566.7M | $6.1B | ||
| Q3 25 | $424.0M | $6.3B | ||
| Q2 25 | $473.6M | $6.4B | ||
| Q1 25 | $515.7M | $5.5B | ||
| Q4 24 | $560.4M | $5.5B | ||
| Q3 24 | $604.0M | $5.5B | ||
| Q2 24 | $620.1M | $5.4B | ||
| Q1 24 | $629.9M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $80.0M |
| Free Cash FlowOCF − Capex | $28.5M | $71.8M |
| FCF MarginFCF / Revenue | 33.5% | 115.8% |
| Capex IntensityCapex / Revenue | 0.1% | 13.3% |
| Cash ConversionOCF / Net Profit | 1.47× | 4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $132.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $80.0M | ||
| Q3 25 | $-46.5M | $26.3M | ||
| Q2 25 | $-43.4M | $29.0M | ||
| Q1 25 | $-47.8M | $11.5M | ||
| Q4 24 | $-134.6M | $51.4M | ||
| Q3 24 | $-29.4M | $16.9M | ||
| Q2 24 | $-30.2M | $18.0M | ||
| Q1 24 | $-29.1M | $12.4M |
| Q4 25 | $28.5M | $71.8M | ||
| Q3 25 | $-46.6M | $24.3M | ||
| Q2 25 | $-43.4M | $27.2M | ||
| Q1 25 | $-48.4M | $8.8M | ||
| Q4 24 | $-138.4M | $44.5M | ||
| Q3 24 | $-31.2M | $16.8M | ||
| Q2 24 | $-30.6M | $17.7M | ||
| Q1 24 | $-29.8M | $12.1M |
| Q4 25 | 33.5% | 115.8% | ||
| Q3 25 | -51765.6% | 39.4% | ||
| Q2 25 | -289620.0% | 50.1% | ||
| Q1 25 | -345635.7% | 18.4% | ||
| Q4 24 | -13837100.0% | 93.8% | ||
| Q3 24 | -1038966.7% | 37.1% | ||
| Q2 24 | -611840.0% | 40.2% | ||
| Q1 24 | -106421.4% | 28.5% |
| Q4 25 | 0.1% | 13.3% | ||
| Q3 25 | 101.1% | 3.1% | ||
| Q2 25 | 440.0% | 3.2% | ||
| Q1 25 | 4507.1% | 5.7% | ||
| Q4 24 | 378600.0% | 14.6% | ||
| Q3 24 | 59266.7% | 0.0% | ||
| Q2 24 | 6980.0% | 0.7% | ||
| Q1 24 | 2535.7% | 0.8% |
| Q4 25 | 1.47× | 4.12× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 6.08× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
